A case series of salvage CCNU in high-grade glioma who have previously received temozolomide from a tertiary care institute in Mumbai.

摘要: INTRODUCTION: In our center, we routinely use CCNU (Lomustine) as salvage treatment in high-grade glioma patients who cannot afford bevacizumab. This exploratory analysis was done to report the efficacy and toxicity associated with this regimen. METHODS: Patients were treated (postexposure temozolomide) between January 2015 August 2016 included for retrospective analysis. SPSS version 16 used Time-to-event performed using Kaplan–Meier method. Progression-free survival (PFS) overall (OS) estimated. The maximum grade of during noted accordance CTCAE 4.02. RESULTS: stipulated period, selected median age 43 years (range 15–63 years), 12 (80.0%) males. Eastern Cooperative Oncology Group performance status 0–1 11 (73.3%) 2–4 4 (26.7%). tumor histopathology at diagnosis glioblastoma ten (66.6%), anaplastic astrocytoma four (26.7%) patients, oligodendroglioma one patient (6.7%). Grade 3–4 myelosuppression seen five (33.3%). PFS OS 192 days (95% confidence interval [CI]: 156.0–227.5 days) 282 CI: 190.9–373.1 days), respectively. CONCLUSION: is modest outcomes recurrent/relapsed gliomas. high rate a concern. Urgent efforts are required improve upon these results.